Document is current
Any future updates will be listed below
-
Authors
Lv, Jiawei
Zheng, Dan-Xue
Liang, Jin-Hui
Zhang, Ning
Ye, Zu-Lu
Xu, Xu-Dong
Chua, Melvin. L. K. https://orcid.org/0000-0002-1648-1473
Zhang, Lu-Lu
Du, Zi-Ming https://orcid.org/0000-0003-2667-4989
Zhang, Zi-Chen
Li, Wen-Fei
Tang, Ling-Long https://orcid.org/0000-0002-8561-1454
Chen, Lei
Mao, Yan-Ping https://orcid.org/0000-0003-1027-071X
Guo, Rui
Chen, Yu-Pei
Lin, Li
Zhang, Yuan
Liu, Xu https://orcid.org/0000-0003-4827-5524
Xu, Cheng
Li, Zhi-Xuan https://orcid.org/0000-0002-8590-875X
Xu, Ling-Xin
Yang, Pan-Yang
Chen, Kun
Bin, Deng
Gao, Tian-Sheng
Yan, Jian-Ye
Chen, Lu-Si
Huang, Shao Hui
Zhao, Hong-Yun https://orcid.org/0000-0002-1251-3888
Hong, Shu-Bin
Jie, Yu-Sheng
Huang, Hui-Ling
Tang, Xu-Hua
Yun, Jing-Ping https://orcid.org/0000-0002-1001-0769
Liu, Li-Zhi
Tian, Li
Li, Hao-Jiang
Li, Ji-Bin https://orcid.org/0000-0001-7632-3648
Zhou, Guan-Qun https://orcid.org/0000-0002-7989-4224
Ma, Jun https://orcid.org/0000-0002-1137-9349
Sun, Ying https://orcid.org/0000-0002-5888-2929
- License Information
-
More Information
Article History
Received: 30 July 2025
Accepted: 4 February 2026
First Online: 11 March 2026
Competing interests
: M.L.K.C. reports personal fees for advisory board and education activities and funding support from BeiGene (tislelizumab) for an investigator-initiated trial; personal fees from TopAlliance Biosciences (toripalimab) for advisory board activities; personal fees from Astellas, Pfizer, MSD, AstraZeneca, Varian, Janssen, IQVIA and Telix Pharmaceuticals; nonfinancial support from AstraZeneca; nonfinancial support from Veracyte; and personal fees and grants from Bayer. M.L.K.C. consults for ImmunoSCAPE; is a co-inventor on the patent ‘High sensitivity lateral flow immunoassay for detection of analyte in sample’ (10202107837T, Singapore); and serves on the board of directors of Digital Life Line, which owns the licensing agreement of the patent. The remaining authors declare no competing interests.
